BioNexus Gene Lab (BGLC) Fundamentals 2026 — Revenue Analysis | SniperIQ
BioNexus Gene Lab (BGLC) is a MY-listed Industrials company in Industrial - Distribution with a market capitalization of
BioNexus Gene Lab (BGLC) has a market capitalization of approximately
BioNexus Gene Lab's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Industrials sector peers rather than read in isolation.
BioNexus Gene Lab runs a net profit margin of -54.7%, a gross margin of 13.5%, and an operating margin of -54.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
BioNexus Gene Lab reported revenue of $7M for fiscal year 2025, with net income of -
BioNexus Gene Lab does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
BioNexus Gene Lab carries a debt-to-equity ratio of 0.03x and a current ratio of 6.52x, with a market beta of 2.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BioNexus Gene Lab (BGLC) the key facts are: market cap
Get BioNexus Gene Lab's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.